Profitability
Weight: 15%
F
16
- 5yr Avg ROIC -26.9%
- Operating Margin Trend +0.00 pp/yr
GLUE
Monte Rosa Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -36.8%
- 5yr Share-Count CAGR 15.6%
Growth Quality
Weight: 35%
C
56
- 5yr Revenue CAGR 63.5%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 1/5
Cash Generation
Weight: 20%
D+
44
- 5yr FCF Margin 14.0%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
C-
48
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 2.82
Stability
Weight: 5%
A-
80
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 new buy; 1 trimmed; 1 full exit.
- Holders
- 2 +1
- Avg Δ position
- -22.4%
- New buys
- 1
- Full exits
- 1